Consenso del Grupo Latinoamericano de estudio de Mieloma Múltiple (MM) GELAMM para el manejo del MM en estado de Pandemia SARS CoV-2 / COVID 19

Recomendaciones Basadas en Consenso de Expertos

  • Humberto Martinez-Codero Instituto Nacional de Cancerología https://orcid.org/0000-0002-7920-5951
  • Lina María Martínez Instituto Nacional de Cancerología, E.S.E
  • Juan Alejandro Ospina
  • Guillermo Ruiz Argüelles
  • Virginia Abello Polo
  • Camila Peña Ojeda
  • Macarena Roa
  • Carlos Fernández de Larrea
  • Rosa Olday Ríos Jiménez
  • Dorotea Fantl
  • Natalia Schutz
  • Eloísa Riva
  • Fiorella Villano
  • Henry Idrobo
  • Virginia Bove
  • Manuel Antonio Granja Morá
  • Marcela Zamora
Palabras clave: COVID-19, mieloma múltiple, tratamiento

Resumen

La enfermedad por COVID-19 fue detectada a finales de 2019 en Wuhan, China. Debido a su rápida propagación fue declarada emergencia sanitaria de forma inicial y luego de identificar casos fuera de China con transmisión autóctona y caracterizado por una mortalidad considerablemente alta en países como Italia y España, fue declarada pandemia por la Organización Mundial de la Salud. Se ha evidenciado que los pacientes mayores y con antecedentes de enfermedades crónicas incluido el cáncer desarrollan una enfermedad severa, presentando mayor riesgo de mortalidad por SARS-CoV2/COVID-19. Lo anterior es por supuesto especialmente importante en el manejo de pacientes con Mieloma Múltiple (MM), generando en el personal Médico nuevos desafíos, oportunidades de mejora y aprendizajes, que aporten al análisis riesgo-beneficio del tratamiento inmunodepresor en este tipo de patologías. 

El consenso tiene como objetivo brindar orientación sobre el manejo de pacientes con MM en estos momentos donde el profesional de la salud requiere información para llevar a cabo terapias eficientes en el cuidado del paciente.

Referencias

Ueda M, Martins R, Hendrie PC, McDonnell T, Crews JR, Wong TL, et al. Managing Cancer Care During the COVID-19 Pandemic: Agility and Collaboration Toward a Common Goal. J Natl Compr Canc Netw 2020 March 20:1-4

Schrag D, Hershman D, Basch E. Oncology Practice During the COVID-19 Pandemic. JAMA. 2020;.

Statista. Población total de América Latina y el Caribe por subregión 2010-2024. 2019. Available at: https://es.statista.com/estadisticas/1067800/poblacion-total-de-america-latina-y-el-caribe-por-subregion/. Accessed Mar 27, 2020.

Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. International Journal of Cancer 2019 Apr 15,;144(8):1941-1953.

Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020; published online Feb 14. http://dx.doi.org/10.1016/ S1470-2045(20)30096-6

Xia Y; Jin R; Zhao J; Li W; Shen H. Risk of COVID-19 for cancer patients. Lancet Oncol. 2020; (published online March 03.

American Society Of Clinical Oncology. COVID-19 Patient Care Information . 2020; Available at: https://www.asco.org/asco-coronavirus-information/care-individuals-cancer-during-covid-19. Accessed Mar 27, 2020

Martínez-Cordero H, Peña C, Schutz NP, Bove V, Villano F, Osorio R, et al. Real World Outcomes in Latin-American Patients with Multiple Myeloma Under 40 Years Old. Blood 2019 Nov 13,;134(Supplement_1):5508.

Limark C, Holmberg E, Mellqvist UH, Landgren O, Bjorkholm M, Hultcrantz M, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015;100(1):107–13.

Saavedra CH. Consenso colombiano de atención, diagnóstico y manejo de la infección por SARS-COV-2/COVI 19 en establecimientos de atención de la salud. recomendaciones basadas en consenso de expertos e informadas en la evidencia. Revista Infectio 2020 Mar,;24(3)

Metodología de expertos consenso en medicina. Serie Monografías N°14: Escuela Andaluza de Salud Pública; 1996.

Centers for Disease Control and Prevention. Coronavirus Disease 2019 (COVID-19) - Transmission. 2020; Available at: https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/how-covid-spreads.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fabout%2Findex.html. Accessed Apr 03, 2020.

World Health Organization. Declared Coronavirus COVID-19 a Pandemic; Available at: https://time.com/5791661/who-coronavirus-pandemic-declaration/. Accessed Mar 27, 2020.

Ebrahim SH, Ahmed QA, Gozzer E, Schlagenhauf P, Memish ZA. Covid-19 and community mitigation strategies in a pandemic. BMJ 2020 Mar 17;368:m1066.

Saavedra CH. Consenso colombiano de atención, diagnóstico y manejo de la infección por SARS-COV-2/COVI 19 en establecimientos de atención de la salud. recomendaciones basadas en consenso de expertos e informadas en la evidencia. Revista Infectio 2020 Mar,;24(3)

Kamboj M, Sepkowitz KA. Nosocomial infections in patients with cancer. Lancet Oncol 2009 June 01;10(6):589-597.

Liang W, Guan W, Chen R et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020; 21: 335-337.

Wang H, Zhang L. Risk of COVID-19 for patients with cancer. Lancet Oncol 2020 March 03.

Attal, M. et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N. Engl. J. Med. 376, 1311–1320 (2017).

Attal, M. et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N. Engl. J. Med. 376, 1311–1320 (2017).

Kamboj M, Sepkowitz KA. Nosocomial infections in patients with cancer. Lancet Oncol 2009 June 01;10(6):589-597.

Liang W, Guan W, Chen R et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020; 21: 335-337.

Wang H, Zhang L. Risk of COVID-19 for patients with cancer. Lancet Oncol 2020 March 03.

Wu V, Moshier E, Leng S, et al. Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling. Blood Adv. 2018;2(12):1470-1479. Blood Adv 2018 September 11;2(17):2186.

Ravi P, Kumar S, Larsen JT, Gonsalves W, Buadi F, Lacy MQ, et al. Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma. Blood Cancer J 2016 July 29;6(7):e454.

Fernandez de Larrea C, Isola I, Pereira A, Cibeira MT, Magnano L, Tovar N, et al. Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression. Leukemia 2018 June 01;32(6):1427-1434.

Perez-Persona E, Vidriales MB, Mateo G, Garcia-Sanz R, Mateos MV, de Coca AG, et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood 2007 October 01;110(7):2586-2592.

Rosinol L, Blade J, Esteve J, Aymerich M, Rozman M, Montoto S, et al. Smoldering multiple myeloma: natural history and recognition of an evolving type. Br J Haematol 2003 November 01;123(4):631-636.

ianchi G, Kyle RA, Larson DR, Witzig TE, Kumar S, Dispenzieri A, et al. High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma. Leukemia 2013 March 01;27(3):680-685.

Lakshman A, Rajkumar SV, Buadi FK, Binder M, Gertz MA, Lacy MQ, et al. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer J 2018 June 12;8(6):59-4.

San Miguel J, Mateos M, Gonzalez V, Dimopoulos MA, Kastritis E, Hajek R, et al. Updated risk stratification model for smoldering multiple myeloma (SMM) incorporating the revised IMWG diagnostic criteria. JCO 2019;37(15):8000

Mateos MV, Hernandez MT, Giraldo P, de la Rubia J, de Arriba F, Lopez Corral L, et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med 2013 August 01;369(5):438-447.

Mateos MV, Hernandez MT, Giraldo P, de la Rubia J, de Arriba F, Corral LL, et al. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial. Lancet Oncol 2016 August 01;17(8):1127-1136.

Lonial S, Jacobus S, Fonseca R, Weiss M, Kumar S, Orlowski RZ, et al. Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma. J Clin Oncol 2019 October 25:JCO1901740.

Korde N, Roschewski M, Zingone A, Kwok M, Manasanch EE, Bhutani M, et al. Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma. JAMA Oncol 2015 September 01;1(6):746-754.

Mateos M-V, Martinez-Lopez J, Rodriguez Otero P, et al: Curative strategy (GEM-CESAR) for high-risk smoldering myeloma (SMM): Carfilzomib, lenalidomide and dexamethasone (KRd) as induction followed by HDT-ASCT, consolidation with KRd and maintenance with Rd. Blood 134:781, 2019 (suppl 1).

Liu C-j, Ghobrial IM, Bustoros M, et al: Phase II trial of combination of elotuzumab, lenalidomide, and dexamethasone in high-risk smoldering multiple myeloma. Blood 132:154, 2018 (suppl 1)

Bustoros M, Nadeem O, Sperling AS, et al: Phase II trial of the combination of ixazomib, lenalidomide, and dexamethasone in high-risk smoldering multiple myeloma. Blood 134:580, 2019 (suppl 1)

Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014 November 01;15(12):538.

Saavedra CH. Consenso colombiano de atención, diagnóstico y manejo de la infección por SARS-COV-2/COVI 19 en establecimientos de atención de la salud. recomendaciones basadas en consenso de expertos e informadas en la evidencia. Revista Infectio 2020 Mar,;24(3)

Willan J, King AJ, Hayes S, Collins GP, Peniket A. Care of haematology patients in a COVID-19 epidemic. Br J Haematol 2020;n/a.

Murrieta-Álvarez I, Steensma DP, Olivares-Gazca JC, Olivares-Gazca M, León-Peña A, Cantero-Fortiz Y, García-Navarrete YI, Cruz-Mora A, Ruiz-Argüelles A, Ruiz-Delgado GJ, Ruiz-Argüelles GJ.Treatment of Persons with Multiple Myeloma in Underprivileged Circumstances: Real-World Data from a Single Institution. Acta Haematol. 2020 Feb 11:1-7. doi: 10.1159/0005056067

Sociedad Americana del Cáncer. Tratamiento - Bifosfonatos - Mieloma Múltiple. Available at: https://www.infocancer.org.mx/?t=tratamiento-bifosfonatos-mieloma-multiple. Accessed 23 mar, 2020.

Asociación Española de Afectados por Linfoma, Mieloma y Leucemia. Enfermedad ósea del mieloma múltiple. 2020; Available at: http://www.aeal.es/mieloma-multiple-espana/11-enfermedad-osea-del-mieloma-multiple/. Accessed 23 mar, 2020.

Sociedad Americana Contra el Cáncer. Terapia con medicamentos para el mieloma múltiple. 2020; Available at: https://www.cancer.org/es/cancer/mieloma-multiple/tratamiento/quimioterapia.html. Accessed 23 mar, 2020

World Health Organization. Infection prevention and control during health care when novel coronavirus (nCoV) infection is suspected. Interim guidance-January 2020. Available at: https://apps.who.int/iris/bitstream/handle/10665/330375/WHO-2019-nCoV-IPC-v2020.1-eng.pdf. Accessed 23 mar, 2020

World Health Organization. Coronavirus disease 2019 (COVID-19)

Situation Report – 51. 2020; Available at: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200311-sitrep-51-covid-19.pdf?sfvrsn=1ba62e57_4. Accessed Mar 27, 2020

Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020 March 01;21(3):335-337.

Hulin C, Belch A, Shustik C, Petrucci MT, Duhrsen U, Lu J, et al. Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial. J Clin Oncol 2016 October 20;34(30):3609-3617.

National Comprehensive Cancer Network. NCCN Guidelines Version 1.2020 Multiple Myeloma. 2019; Available at: http://szpiczak.org/wp-content/uploads/aktualnosci/2020/myeloma-NCCN-2020.pdf. Accessed Mar 26, 2020.

Rajkumar SV. Multiple myeloma: 2018 update on diagnosis, risk‐stratification, and management. American Journal of Hematology 2018 Aug;93(8):1091-1110.

Moreau P, San Miguel J, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2017;28:iv52-iv61.

Durie BGM, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 2017 February 04;389(10068):519-527.

Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M, et al. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. Lancet Oncol 2014 December 01;15(13):1503-1512.

Maschmeyer G, Beinert T, Buchheidt D, et al. Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients: guidelines of the Infectious Diseases Working Party of the German Society of Haematology and Oncology. Eur J Cancer 2009; 45:2462–72.

Alanio A, Hauser PM, Lagrou K, et al; 5th European Conference on Infections in Leukemia (ECIL-5), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the Immunocompromised Host Society (ICHS) and the European LeukemiaNet (ELN). ECIL guidelines for the diagnosis of Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother 2016; 71:2386–96.

Freifeld AG, Bow EJ, Sepkowitz KA, et al; Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011; 52:e56–93.

Ravi P, Kumar SK, Cerhan JR, Maurer MJ, Dingli D, Ansell SM, et al. Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies. Blood cancer journal 2018 Feb 28,;8(3):26-7. Harousseau JL, Attal M. How I treat first relapse of myeloma. Blood 2017 Aug 24,;130(8):963-973.

Willan J, King AJ, Hayes S, Collins GP, Peniket A. Care of haematology patients in a COVID-19 epidemic. British journal of haematology 2020 Mar 15.

Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014 November 01;15(12):538.

Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020 March 01;21(3):335-337.

Xia Y, Jin R, Zhao J, Li W, Shen H. Risk of COVID-19 for cancer patients. Lancet Oncol 2020 March 03

American Society Of Clinical Oncology. COVID-19 Patient Care Information . 2020; Available at: https://www.asco.org/asco-coronavirus-information/care-individuals-cancer-during-covid-19. Accessed Mar 27, 2020

Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020 March 01;21(3):335-337.

Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. JAMA 2020 Mar 23.

Ueda M, Martins R, Hendrie PC, et al. Managing Cancer Care During the COVID-19 Pandemic: Agility and Collaboration Toward a Common Goal. J Natl Compr Canc Netw. 2020 Mar 20:1-4. doi: 10.6004/jnccn.2020.7560. [Epub ahead of print]

Willan J, King AJ, Hayes S, Collins GP, Peniket A. Care of haematology patients in a COVID-19 epidemic. British journal of haematology 2020 Mar 15.

Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. The Lancet Oncology 2020 Mar;21(3):335-337.

Willan J, King AJ, Hayes S, Collins GP, Peniket A. Care of haematology patients in a COVID-19 epidemic. British journal of haematology 2020 Mar 15.

Saavedra CH. Consenso colombiano de atención, diagnóstico y manejo de la infección por SARS-COV-2/COVI 19 en establecimientos de atención de la salud. recomendaciones basadas en consenso de expertos e informadas en la evidencia. Revista Infectio 2020 Mar,;24(3)

Ornanización Mundial de la Salud. Cuándo y cómo usar mascarilla. Disponible en: https://www.who.int/es/emergencies/diseases/novel-coronavirus-2019/advice-for-public/when-and-how-to-use-masks. Acceso 27 Mar, 2020.

Publicado
2020-05-22
Sección
Artículos especiales